Aratana Therapeutics Company Profile (NASDAQ:PETX)

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PETX
  • CUSIP: N/A
  • Web: www.aratana.com
Capitalization:
  • Market Cap: $223.57 million
  • Outstanding Shares: 37,957,000
Average Prices:
  • 50 Day Moving Avg: $5.93
  • 200 Day Moving Avg: $6.77
  • 52 Week Range: $4.97 - $10.73
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.73
  • P/E Growth: -0.36
Sales & Book Value:
  • Annual Revenue: $42.17 million
  • Price / Sales: 5.30
  • Book Value: $2.19 per share
  • Price / Book: 2.69
Profitability:
  • EBIDTA: ($16,310,000.00)
  • Net Margins: -60.32%
  • Return on Equity: -19.87%
  • Return on Assets: -13.14%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 5.18%
  • Quick Ratio: 4.92%
Misc:
  • Average Volume: 469,710 shs.
  • Beta: 3.65
  • Short Ratio: 6.11
 

Frequently Asked Questions for Aratana Therapeutics (NASDAQ:PETX)

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.34). The business earned $3.80 million during the quarter, compared to the consensus estimate of $3.05 million. Aratana Therapeutics had a negative net margin of 60.32% and a negative return on equity of 19.87%. Aratana Therapeutics's revenue was up 2135.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.52) EPS. View Aratana Therapeutics' Earnings History.

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?

6 analysts have issued 1 year price targets for Aratana Therapeutics' shares. Their forecasts range from $7.00 to $15.00. On average, they expect Aratana Therapeutics' stock price to reach $10.40 in the next twelve months. View Analyst Ratings for Aratana Therapeutics.

What are analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (5/10/2017)
  • 2. Jefferies Group LLC analysts commented, "Q4'16 results uneventful. The Nocita and Galliprant launches are progressing and Entyce is on track for late '17 launch. However, we think the sell-off on the Q4 results was primarily driven by concerns around the cash runway and how this will be addressed. We like the risk/ reward at this level and reiterate our Buy rating. PT lowered to $8 (from $11)." (3/16/2017)
  • 3. Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)

Who are some of Aratana Therapeutics' key competitors?

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (10.07%), Vanguard Group Inc. (5.16%), Janus Capital Management LLC (3.88%), Wellington Management Group LLP (3.38%), AWM Investment Company Inc. (2.84%) and Massachusetts Financial Services Co. MA (2.64%). Company insiders that own Aratana Therapeutics stock include Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Jennison Associates LLC, Cornerstone Capital Management Holdings LLC., Acadian Asset Management LLC, American Century Companies Inc., Morgan Stanley, TIAA CREF Investment Management LLC and Wellington Management Group LLP. Company insiders that have sold Aratana Therapeutics stock in the last year include Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Tocqueville Asset Management L.P., Dimensional Fund Advisors LP, AWM Investment Company Inc., Capital Fund Management S.A., Tudor Investment Corp ET AL and Woodstock Corp. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aratana Therapeutics stock cost?

One share of Aratana Therapeutics stock can currently be purchased for approximately $5.89.

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.40 (76.57% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2017Jefferies Group LLCReiterated RatingBuy$8.00MediumView Rating Details
5/10/2017Stifel NicolausLower Price TargetBuy -> Buy$8.00 -> $7.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$15.00N/AView Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
8/10/2016Credit Suisse Group AGReiterated RatingBuy$11.00N/AView Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00N/AView Rating Details
11/4/2015Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $15.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Aratana Therapeutics (NASDAQ:PETX)
Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Earnings History by Quarter for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.35)($0.29)($0.31)
Q2 20173($0.33)($0.28)($0.30)
Q3 20173($0.30)($0.26)($0.29)
Q4 20173($0.32)($0.09)($0.23)
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aratana Therapeutics (NASDAQ:PETX)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 75.44%
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aratana Therapeutics (NASDAQ:PETX)
Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
Source:
DateHeadline
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 23 at 2:20 PM
prnewswire.com logoAratana Therapeutics to Participate at Three Upcoming Investment ... - PR Newswire (press release)
www.prnewswire.com - May 17 at 8:34 AM
finance.yahoo.com logoAratana Therapeutics to Participate at Three Upcoming Investment Conferences
finance.yahoo.com - May 16 at 9:55 AM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 14 at 8:58 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Price Target Lowered to $7.00 at Stifel Nicolaus
www.americanbankingnews.com - May 14 at 4:00 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - May 14 at 2:22 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Expected to Post Quarterly Sales of $4.6 Million
www.americanbankingnews.com - May 13 at 8:00 AM
americanbankingnews.com logoAnalysts Set Expectations for Aratana Therapeutics Inc's Q2 2017 Earnings (PETX)
www.americanbankingnews.com - May 12 at 8:50 AM
americanbankingnews.com logo-$0.33 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - May 11 at 8:20 PM
americanbankingnews.com logoAratana Therapeutics Inc to Post FY2019 Earnings of $0.35 Per Share, William Blair Forecasts (PETX)
www.americanbankingnews.com - May 11 at 3:20 PM
finance.yahoo.com logoEdited Transcript of PETX earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 11:44 AM
finance.yahoo.com logoInvestor Network: Aratana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 11:11 AM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 10:22 AM
finance.yahoo.com logoAratana Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 6:34 PM
marketbeat.com logoAratana reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Set to Announce Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 10:47 PM
finance.yahoo.com logoBiotech Movers: Aratana Offering Priced Below Market, Shares Fall
finance.yahoo.com - May 4 at 7:22 PM
finance.yahoo.com logoAratana Therapeutics Announces Pricing of Registered Direct Offering - Yahoo Finance
finance.yahoo.com - May 4 at 8:07 AM
finance.yahoo.com logoAratana Therapeutics Announces Pricing of Registered Direct Offering
finance.yahoo.com - May 3 at 7:52 PM
americanbankingnews.com logoPositive News Coverage Extremely Likely to Affect Aratana Therapeutics (PETX) Stock Price
www.americanbankingnews.com - May 2 at 1:36 PM
americanbankingnews.com logoSomewhat Critical News Coverage Unlikely to Affect Aratana Therapeutics (PETX) Share Price
www.americanbankingnews.com - April 29 at 3:35 PM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 28 at 4:39 PM
americanbankingnews.com logo$4.29 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - April 28 at 1:03 AM
streetinsider.com logoAratana Therapeutics (PETX) Provides Update on ENTYCE Following Meeting with FDA CVM
www.streetinsider.com - April 25 at 6:21 PM
finance.yahoo.com logoAratana Therapeutics Provides Update on ENTYCE®
finance.yahoo.com - April 25 at 6:21 PM
americanbankingnews.com logoAratana Therapeutics (PETX) Receives Daily Media Sentiment Rating of 0.24
www.americanbankingnews.com - April 24 at 7:08 PM
finance.yahoo.com logoAratana Therapeutics to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 24 at 4:16 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Conatus Pharma, Grifols, Aratana Therapeutics, and - PR Newswire (press release)
www.prnewswire.com - April 22 at 12:22 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Conatus Pharma, Grifols, Aratana Therapeutics, and Agios Pharma
www.bizjournals.com - April 21 at 9:02 AM
americanbankingnews.com logo Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 21 at 12:13 AM
americanbankingnews.com logoAratana Therapeutics Inc (PETX) Insider Peter Steven St Sells 50,000 Shares
www.americanbankingnews.com - April 18 at 7:55 PM
americanbankingnews.com logoAratana Therapeutics (PETX) Receives News Sentiment Rating of 0.24
www.americanbankingnews.com - April 17 at 11:51 PM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana ... - Yahoo Finance
finance.yahoo.com - April 9 at 6:41 PM
finance.yahoo.com logoETFs with exposure to Aratana Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:33 PM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017
finance.yahoo.com - April 7 at 11:51 AM
finance.yahoo.com logoAPRIL 7 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 7 at 11:51 AM
finance.yahoo.com logoDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017
finance.yahoo.com - April 7 at 11:51 AM
finance.yahoo.com logoDEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - April 7 at 11:51 AM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline - April 7, 2017
finance.yahoo.com - April 7 at 11:51 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017
finance.yahoo.com - April 3 at 6:33 PM
finance.yahoo.com logo4-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - April 3 at 6:33 PM
globenewswire.com logoPETX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class ... - GlobeNewswire (press release)
globenewswire.com - April 1 at 11:12 AM
prnewswire.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - April 1 at 11:12 AM
finance.yahoo.com logoPETX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Aratana Therapeutics, Inc. and a Lead Plaintiff Deadline of April 7, 2017
finance.yahoo.com - March 31 at 7:18 PM
finance.yahoo.com logoONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 7:18 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. - PETX
finance.yahoo.com - March 31 at 7:18 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) & Lead Plaintiff Deadline - April 7, 2017
finance.yahoo.com - March 30 at 7:26 PM
finance.yahoo.com logoDEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 7:26 PM
businesswire.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Aratana ... - Business Wire (press release)
www.businesswire.com - March 29 at 12:00 AM

Social

Chart

Aratana Therapeutics (PETX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff